As part of the Horizon 2020 CARAMBA project, Myeloma Patients Europe (MPE) interviewed experts on different aspects of the CARAMBA clinical trial: manufacturing process, safety updates, and immune monitoring. The videos were filmed during the ASH annual meeting in December 2022. The CARAMBA project is a phase I/II clinical trial investigating innovative immunotherapy for treating myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide range of stakeholders, including MPE, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory to myeloma patients in the clinic.
CARAMBA is specifically looking at targeting CAR-T at a protein called SLAMF7 which is expressed on the surface of myeloma cells. The safety and efficacy of SLAMF7-specific CAR-T cells are assessed in myeloma patients through this clinical trial. This therapy involves collecting a type of white blood cell which makes up part of the immune system (T-cells) from patients and equipping them with a synthetic chimeric antigen receptor (CAR). When reintroduced into patients’ bodies, the CAR acts like a sensor boosting the ability of the T-cells to find and kill myeloma cells.
You can watch the videos here:
Prof. Dr. Halvard B. Bönig, Professor for Translational Development of Cellular Therapeutics at Goethe University, Frankfurt, Germany
Dr. Bruno Paiva, Scientific Coordinator of the Diagnostic Laboratories of the University of Navarra, Spain
Prof. Dr. Ibrahim Yakoub-Agha, Head of the Hematopoietic Cell Transplantation Unit at Lille University Hospital, France
Explore MPE CAR-T resources here.
For further information about Horizon2020 CARAMBA, please visit the CARAMBA website.